Free Trial

10x Genomics (TXG) Stock Price, News & Analysis

10x Genomics logo
$21.60 -0.82 (-3.66%)
Closing price 04:00 PM Eastern
Extended Trading
$21.65 +0.05 (+0.23%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About 10x Genomics Stock (NASDAQ:TXG)

Advanced

Key Stats

Today's Range
$19.82
$21.99
50-Day Range
$16.69
$26.08
52-Week Range
$8.06
$26.44
Volume
4.83 million shs
Average Volume
2.61 million shs
Market Capitalization
$2.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.82
Consensus Rating
Hold

Company Overview

10x Genomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

TXG MarketRank™: 

10x Genomics scored higher than 29% of companies evaluated by MarketBeat, and ranked 722nd out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 1 strong buy rating, 5 buy ratings, 9 hold ratings, and 2 sell ratings.

  • Upside/Downside

    The consensus price target for 10x Genomics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    10x Genomics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about 10x Genomics' stock forecast and price target.
  • Earnings Growth

    Earnings for 10x Genomics are expected to grow in the coming year, from ($0.93) to ($0.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 10x Genomics is -127.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 10x Genomics is -127.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    10x Genomics has a P/B Ratio of 3.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    14.23% of the float of 10x Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 7.14.
  • Change versus previous month

    Short interest in 10x Genomics has recently increased by 2.83%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    10x Genomics does not currently pay a dividend.

  • Dividend Growth

    10x Genomics does not have a long track record of dividend growth.

  • News Sentiment

    10x Genomics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for 10x Genomics this week, compared to 5 articles on an average week.
  • Search Interest

    13 people have searched for TXG on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $902,695.00 in company stock.

  • Percentage Held by Insiders

    8.84% of the stock of 10x Genomics is held by insiders.

  • Percentage Held by Institutions

    84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 10x Genomics' insider trading history.
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TXG Stock News Headlines

10x Genomics: Q1 Earnings Snapshot
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the biggest story of his 26-year career - an economic shift not seen since 1776. From the government taking stakes in Intel, Lithium Americas, and MP Materials, to sweeping political changes reshaping the economy, Stansberry argues a rare 'New 1776 Moment' is already underway. One Nobel Prize winner calls it a dividing line for all of society. His presentation covers the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.tc pixel
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
10x Genomics (TXG) Stock Falls on Q1 2026 Earnings
10x Genomics (NASDAQ:TXG) CEO Sells $122,800.00 in Stock
See More Headlines

TXG Stock Analysis - Frequently Asked Questions

10x Genomics' stock was trading at $16.31 on January 1st, 2026. Since then, TXG shares have increased by 32.4% and is now trading at $21.60.

10x Genomics (NASDAQ:TXG) released its earnings results on Thursday, May, 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.19. The firm's revenue was up 9.4% on a year-over-year basis.
Read the conference call transcript
.

10x Genomics (TXG) raised $370 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 10,000,000 shares at $36.00-$38.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

10x Genomics' top institutional investors include Sumitomo Mitsui Trust Group Inc. (4.00%), Amova Asset Management Americas Inc. (4.00%), Dimensional Fund Advisors LP (1.60%) and Simplify Asset Management Inc. (0.28%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Mathai Mammen, Justin J Mcanear, James Wilbur and Alan Mateo.
View institutional ownership trends
.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/07/2026
Today
5/08/2026
Bank of America Global Healthcare Conference 2026
5/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TXG
CIK
1770787
Fax
N/A
Employees
1,240
Year Founded
2012

Price Target and Rating

High Price Target
$32.00
Low Price Target
$6.50
Potential Upside/Downside
+2.6%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.54 million
Net Margins
-6.77%
Pretax Margin
-6.21%
Return on Equity
-6.89%
Return on Assets
-5.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.46
Quick Ratio
4.09

Sales & Book Value

Annual Sales
$642.82 million
Price / Sales
4.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.24 per share
Price / Book
3.25

Miscellaneous

Outstanding Shares
127,750,000
Free Float
116,459,000
Market Cap
$2.59 billion
Optionable
Optionable
Beta
2.05

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:TXG) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners